Can the Moderna and BioNTech Bulls Keep Running?
_0.png?locale=de){kind=logo}
Positive results from clinical trials with their coronavirus vaccine candidates have pushed shares of Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) into the clouds. Neither of these companies has developed a marketable product yet, but their market caps have risen to a combined $62 billion at recent prices.
With plenty of competition on the way, neither of these companies can justify their recent stock-market valuations with potential sales from just one coronavirus vaccine. Can these companies be expected to produce multiple blockbuster drugs? Here's what you need to know about the road ahead for Moderna, BioNTech, and a wave of younger businesses developing similar drugs.
Image source: Getty Images.
Source Fool.com
